share_log
  • Headlines
  • Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations

Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations

Benzinga ·  Oct 3 19:42
Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated